Overview

Azithromycin in Idiopathic Pulmonary Fibrosis

Status:
Completed
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with no cure available. Patients suffer from respiratory symptoms including dyspnea and cough. To improve life quality the investigators will test the effects of immunomodulation of macrolides specifically on cough in IPF patients. The investigators hypothesize that immunomodulatory treatment reduces cough frequency and might improve lung function.
Phase:
N/A
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborator:
University of Bern
Treatments:
Azithromycin